A detailed history of Shelton Capital Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Shelton Capital Management holds 5,121 shares of HALO stock, worth $243,452. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,121
Previous 5,121 -0.0%
Holding current value
$243,452
Previous $268,000 8.96%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$37.81 - $52.4 $23,215 - $32,173
-614 Reduced 10.71%
5,121 $268,000
Q4 2023

Feb 14, 2024

SELL
$33.32 - $42.1 $18,925 - $23,912
-568 Reduced 9.01%
5,735 $211,000
Q2 2023

Aug 10, 2023

SELL
$30.28 - $38.74 $16,926 - $21,655
-559 Reduced 8.15%
6,303 $227,000
Q4 2022

Feb 13, 2023

SELL
$40.06 - $59.44 $16,504 - $24,489
-412 Reduced 5.66%
6,862 $390,000
Q4 2020

Feb 16, 2021

BUY
$25.81 - $43.62 $187,741 - $317,291
7,274 New
7,274 $311,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.